Schizophrenia – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Schizophrenia – Pipeline Review, H2 2019’, provides an overview of the Schizophrenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”


– The report provides a snapshot of the global therapeutic landscape of Schizophrenia

– The report reviews pipeline therapeutics for Schizophrenia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Schizophrenia therapeutics and enlists all their major and minor projects

– The report assesses Schizophrenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Schizophrenia”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Schizophrenia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AbbVie Inc

Acadia Pharmaceuticals Inc

Adamed Sp zoo

Adeptio Pharmaceuticals Ltd

Aequus Pharmaceuticals Inc

AgeneBio Inc

Alkermes Plc

Athersys Inc

Autifony Therapeutics Ltd

Avanir Pharmaceuticals Inc

Avicanna Inc

AviMed Pharmaceuticals LLC

Avineuro Pharmaceuticals Inc

BCWorld Pharm Co Ltd

Beloteca Inc

Biogen Inc

BioHealthonomics Inc

BioStem Technologies Inc

BioStratum Inc

BioXcel Therapeutics Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Cadent Therapeutics Inc

Cerevance Inc

Cerevel Therapeutics LLC

Concert Pharmaceuticals Inc

Curemark LLC

CuroNZ Ltd

Daewoong Pharmaceutical Co Ltd

Daya Drug Discoveries Inc

Delpor Inc

Denovo Biopharma LLC

Enterin Inc

F. Hoffmann-La Roche Ltd

Fabre-Kramer Pharmaceuticals Inc

Gabather AB

Genentech Inc

GlaxoSmithKline Plc

GP Pharm SA

GW Pharmaceuticals Plc

H. Lundbeck AS

Impel NeuroPharma Inc

Insys Therapeutics Inc

IntelGenx Corp

Intra-Cellular Therapies Inc

IRLAB Therapeutics AB

Jiangsu Nhwa Pharmaceutical Corp Ltd

Johnson & Johnson

Karuna Therapeutics Inc

KemPharm Inc

Laboratorios Farmaceuticos Rovi SA

Lb Pharmaceuticals Inc

Lead Discovery Center GmbH

Lohocla Research Corp

Luye Pharma Group Ltd

Lyndra Inc

Mapi Pharma Ltd

MedinCell SA

Mental-Heal Ltd

Merck & Co Inc

Mitsubishi Tanabe Pharma Corp

Neurocea Pharmaceuticals

Neurocrine Biosciences Inc

NeurOp Inc

NeuroSolis Inc

Newron Pharmaceuticals SpA

Omeros Corp

Orbis Biosciences Inc

Otsuka Holdings Co Ltd

Ra Pharmaceuticals Inc

Reviva Pharmaceuticals Inc

Richter Gedeon Nyrt

Schrodinger LLC

Sichuan Kelun Pharmaceutical Co Ltd

Siragen Pharmaceuticals Inc

SkySea Pharmaceutical Inc

Sosei Heptares

Sumitomo Dainippon Pharma Co Ltd

Sunovion Pharmaceuticals Inc

SyneuRx International Corp

Taho Pharmaceuticals Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Terran Biosciences Inc

Teva Pharmaceutical Industries Ltd

Vanda Pharmaceuticals Inc

Vitality Biopharma Inc

Zysis Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Schizophrenia Overview 7

Schizophrenia Therapeutics Development 8

Schizophrenia Therapeutics Assessment 23

Schizophrenia Companies Involved in Therapeutics Development 37

Schizophrenia Drug Profiles 71

Schizophrenia Dormant Projects 285

Schizophrenia Discontinued Products 294

Schizophrenia Product Development Milestones 297

Appendix 307

List of Tables

“List of Tables

Number of Products under Development for Schizophrenia, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Schizophrenia – Pipeline by AbbVie Inc, H2 2019

Schizophrenia – Dormant Projects, H2 2019

Schizophrenia – Discontinued Products, H2 2019”


Discounts available for multiple report purchases.
+44 (0) 161 359 5414

Saved reports